Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Maps Pathways To Compliance At Unapproved Drugs Workshop

This article was originally published in The Tan Sheet

Executive Summary

FDA plans to increase enforcement actions against marketed unapproved drugs in the coming year, but hopes to cooperate with firms willing to come to the table seeking approval for currently unapproved products
Advertisement

Related Content

FDA Sounds Off On Unapproved Ear Drops Through Enforcement Notice
FDA Sounds Off On Unapproved Ear Drops Through Enforcement Notice
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
FDA Employs Carrot, Stick Under Unapproved Drug Enforcement Strategy
Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products

Topics

Advertisement
UsernamePublicRestriction

Register

PS100117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel